Education
About Us
Working with TipRanks
Follow Us
AlzeCure Pharma AB (SE:ALZCUR)
FRANKFURT:ALZCUR
Top Page
AlzeCure Pharma AB
(Frankfurt:ALZCUR)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr2.00
▼(-18.03% Downside)
The score is held down primarily by weak financial performance (no revenue, large ongoing losses, and sustained negative free cash flow implying funding risk) and a weak technical setup (below major moving averages with negative MACD). Valuation provides limited support due to the negative P/E and lack of dividend yield data.
Positive Factors
Low Leverage
Low leverage provides financial flexibility and reduces the risk of financial distress, supporting long-term operational stability.
Moderating Cash Burn
A reduction in cash burn indicates improved operational efficiency, potentially extending the company's runway for development activities.
Focus on CNS Disorders
Specialization in CNS disorders, including Alzheimer's, positions the company in a high-demand market with significant unmet needs.
Negative Factors
No Revenue Generation
Lack of revenue generation limits financial sustainability and increases reliance on external funding, posing a risk to long-term viability.
Sustained Losses
Persistent losses indicate ongoing financial challenges, potentially leading to further dilution and impacting shareholder value.
Negative Free Cash Flow
Negative free cash flow reflects ongoing cash consumption, which may necessitate additional financing and affect future growth prospects.
AlzeCure Pharma AB (ALZCUR) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr209.72M
Dividend YieldN/A
Average Volume (3M)52.87K
Price to Earnings (P/E)―
Beta (1Y)-0.11
Revenue GrowthN/A
EPS Growth15.74%
CountrySE
Employees11
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.09
Shares Outstanding114,914,450
10 Day Avg. Volume28,042
30 Day Avg. Volume52,872
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.36
Price to Sales (P/S)0.00
P/FCF Ratio-2.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AlzeCure Pharma AB Business Overview & Revenue Model
Company DescriptionAlzeCure Pharma AB (ALZCUR) is a Swedish pharmaceutical company that focuses on developing innovative therapies for neurodegenerative diseases, with a particular emphasis on Alzheimer's disease and pain management. The company operates in the biotechnology sector, leveraging its expertise in neuroscience to advance its pipeline of drug candidates. AlzeCure's core products include a range of proprietary small molecule drugs that target key pathways involved in neurodegeneration.
How the Company Makes MoneyAlzeCure Pharma AB generates revenue primarily through the development and potential commercialization of its pharmaceutical candidates. The company invests in research and development to advance its drug pipeline towards clinical trials, seeking partnerships and collaborations with larger pharmaceutical firms to co-develop or license its technologies. Licensing agreements and milestone payments from such partnerships contribute significantly to the company's revenue. Additionally, AlzeCure may receive funding from grants and public or private investments to support its ongoing research efforts. The strategic focus on addressing unmet medical needs in neurodegenerative diseases positions AlzeCure to potentially capture market share upon successful drug approval and commercialization.
AlzeCure Pharma AB Financial Statement Overview
Summary
AlzeCure Pharma AB is in a typical pre-revenue pharmaceutical phase, with no revenues but high R&D expenses leading to financial losses. The balance sheet remains debt-free with substantial equity but is gradually depleting. Cash flow management is reliant on external financing, highlighting the need for successful product development and eventual revenue generation.Income Statement
AlzeCure Pharma AB has consistently reported zero revenue over the years, indicating the company is still in pre-revenue stages, typical of many pharmaceutical companies awaiting product approval. However, this results in substantial operating losses, with negative EBIT and net income figures, which highlight the financial strain of ongoing operations without income.Balance Sheet
The company's balance sheet shows a strong equity position, with no debt reported, leading to a healthy equity ratio. However, the consistent decline in total assets and equity over time could pose a risk if revenue generation does not materialize soon.Cash Flow
AlzeCure Pharma AB has negative free cash flow, indicating cash outflows exceed cash generated, a common scenario for R&D-focused pharmaceutical firms. While operating cash flow has shown some improvement, the company heavily relies on financing activities to sustain operations.| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -395.00K | -293.00K | -476.00K | -570.00K | -576.00K | -495.00K |
| EBITDA | -38.70M | -35.70M | -37.87M | -55.67M | -77.20M | -70.87M |
| Net Income | -39.20M | -35.23M | -37.17M | -56.04M | -77.78M | -71.37M |
Balance Sheet | ||||||
| Total Assets | 66.59M | 34.44M | 32.00M | 70.84M | 45.65M | 117.83M |
| Cash, Cash Equivalents and Short-Term Investments | 59.19M | 31.50M | 29.10M | 25.58M | 41.74M | 112.43M |
| Total Debt | 2.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 15.93M | 8.25M | 8.23M | 10.35M | 12.67M | 7.07M |
| Stockholders Equity | 50.66M | 26.18M | 23.77M | 60.48M | 32.97M | 110.75M |
Cash Flow | ||||||
| Free Cash Flow | -26.00M | -35.25M | 3.06M | -99.91M | -70.69M | -70.18M |
| Operating Cash Flow | -25.87M | -35.12M | 3.06M | -99.91M | -70.64M | -69.51M |
| Investing Cash Flow | -124.00K | -124.00K | 7.00K | 0.00 | -54.00K | -671.00K |
| Financing Cash Flow | 54.23M | 37.65M | 459.00K | 83.75M | 0.00 | 114.00K |
AlzeCure Pharma AB Technical Analysis
Negative
2.44
Price Trends
2.12
Negative
2.63
Negative
2.66
Negative
Market Momentum
-0.06
Positive
45.43
Neutral
41.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALZCUR, the sentiment is Negative. The current price of 2.44 is above the 20-day moving average (MA) of 2.15, above the 50-day MA of 2.12, and below the 200-day MA of 2.66, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 45.43 is Neutral, neither overbought nor oversold. The STOCH value of 41.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ALZCUR.
AlzeCure Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:ALZCUR
AlzeCure Pharma AB
2.00
0.72
56.23%
ORXOF
Orexo AB
3.76
2.68
248.15%
DE:6FN
Klaria Pharma Holding AB
0.06
0.04
180.00%
DE:40M
Nanexa AB
0.31
0.15
86.83%
SE:ENZY
Enzymatica AB
2.05
0.44
27.33%
SE:ERMA
Enorama Pharma AB
2.01
-1.48
-42.41%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.